Increasing Epilepsy Cases Boost Demand For Cannabis-Based Treatments Emerges as a Core Driver of the Cannabis Pharmaceuticals Market in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Cannabis Pharmaceuticals Market Through 2025?
The valuation of the cannabis pharmaceuticals sector has seen tremendous expansion recently, projected to climb from $6.03 billion in the year 2024 to a substantial $9.43 billion by 2025, reflecting an impressive compound annual growth rate (CAGR) of 56.4%. This remarkable upward trajectory during the past period is rooted in several key factors, including the broadening acceptance of medical cannabis legally, heightened understanding regarding the medicinal advantages of can*nabinoids, the increasing incidence of long-term and brain-related medical conditions, the establishment of favorable governmental regulations, escalating financial commitments within the pharmaceutical industry, and a noticeable alteration in societal views regarding the incorporation of cannabis within medical treatments.

What's the Projected Size of the Global Cannabis Pharmaceuticals Market by 2029?
Projections indicate that the cannabis pharmaceuticals sector is poised for rapid expansion over the fort*hcoming period, reaching a valuation of $55.53 billion by 2029, fueled by a compound annual growth rate (CAGR) soaring to 55.8%. This substantial upward trajectory during the projection timeframe is underpinned by several factors, such as the proliferation of regulatory endorsements, heightened public knowledge concerning the therapeutic advantages of medical cannabis, broader utilization in addressing pain and various neurological conditions, the increasing incidence of long-term health issues, advancements in methods for administering these drugs, and the implementation of supportive financial recompense frameworks. Key developments anticipated to shape this market moving forward encompass progress in methods for isolating cann*abinoids, creation of more precise drug administration mechanisms, increased utilization of lab-synthesized canna*binoid compounds, refinement of procedures for conducting clinical studies, and the incorporation of artificial intelligence tools within the realm of pharmaceutical discovery.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report

Top Growth Drivers in the Cannabis Pharmaceuticals Industry: What's Accelerating the Market?
Anticipated growth in the prevalence of epilepsy is set to propel the cannabis pharmaceuticals sector forward. Epilepsy, defined as a central nervous system condition involving recurring, spontaneous seizures stemming from erratic electrical patterns within the brain, is seeing increased case numbers due to improved diagnostic capabilities, greater public understanding, and more thorough reporting, coupled with possible contributions from environmental factors, genetic predispositions, and lifestyle choices. Pharmaceutical applications of cannabis, particularly through can*nabinoids such as CB*D, present a promising avenue for epilepsy management by potentially lessening the frequency and intensity of seizures, especially for individuals unresponsive to standard anti-seizure medications. To illustrate the scope, data from the European Brain Council, a non-profit organization headquartered in Belgium, indicated in April 2022 that more than 600 neurological disorders and approximately 300 mental health conditions affect millions worldwide, with epilepsy accounting for 65 million sufferers. Furthermore, projections from the Alzheimer Society of Canada, a Canadian health-focused charity, suggested in July 2024 that an estimated 771,939 people in Canada would be diagnosed with dementia by January 1, 2025, a figure expected to approach one million by 2030. Consequently, the escalating occurrence of epilepsy serves as a key stimulus for expansion within the market for cannabis-derived pharmaceuticals.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp

What Trends Will Shape the Cannabis Pharmaceuticals Market Through 2029 and Beyond?
Key players within the cannabis pharmaceuticals sector are concentrating their efforts on creating novel offerings, notably sophisticated medical cannabis preparations intended to manage various ailments and enhance therapeutic results for patients. Such cutting-edge medical cannabis compositions denote meticulously engineered cannabis-derived goods structured for optimal medicinal application, featuring exact concentrations of active compounds like cann*abidiol (CB*D) and tetrahydrocannabinol (T*HC). A relevant illustration is the granting of production and controlled-substance authorizations by Swissmedic in April 2024 to Canexis Pharma AG, a pharmaceutical entity situated in Switzerland. These endorsements authorize the firm to manufacture superior medicinal starting materials sourced from both CB*D and TH*C, thereby enabling Canexis to satisfy escalating requirements for medical cannabis across Switzerland and internationally. Gaining these necessary permits substantiates the firm's adherence to rigorous regulatory benchmarks, bolstering its standing and capacity to participate significantly in the fast-advancing medical cannabis arena.

What Are the Main Segments in the Cannabis Pharmaceuticals Market?
The cannabis pharmaceuticalsmarket covered in this report is segmented -

1) By Product Type: Canna*binoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Canna*binoids
2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions
3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management
4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations

Subsegments:
1) By Cannab*inoid-Based Pharmaceuticals: T*HC-Based Pharmaceuticals; CB*D-Based Pharmaceuticals; Combination of T*HC and CB*D Pharmaceuticals; Other Cann*abinoid-Based Formulations
2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CB*D Isolate)
3) By Synthetic Ca*nnabinoids: Synthetic T*HC Analogues; Synthetic CB*D Analogues; Synthetic Can*nabinoid Receptor Agonists; Designer Synthetic Cann*abinoids

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp

Which Top Companies are Driving Growth in the Cannabis Pharmaceuticals Market?
Major companies operating in the cannabis pharmaceuticals market are Curaleaf Holdings Inc., Aphria Inc., Green Thumb Industries Inc., Trulieve Cannabis Corp., Tilray Inc., Cresco Labs Inc., Columbia Care Inc., Acreage Holdings Inc., Canopy Growth Corporation, Aurora Cannabis Inc., MedMen Enterprises Inc., OrganiGram Holdings Inc., Cronos Group, Enveric Biosciences Inc., Auxly Cannabis Group Inc., Valens Company Inc., Charlotte's Web Holdings Inc., Medical Marijuana Inc., Aleafia Health Inc., Supreme Cannabis Company Inc., Avicanna Inc., Emerald Health Therapeutics Inc.

Which Regions Will Dominate the Cannabis Pharmaceuticals Market Through 2029?
North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.